Researchers have determined which set of human genes help fight the infection that is known to cause COVID-19, the SARS-CoV-2. This information could be beneficial in helping researchers understand the factors that influence the ailment’s severity, in addition to assisting in the formulation of therapies for the said disease. The research was reported in the “Molecular Cell” journal.
The genes, which were identified by researchers from the Sanford Burnham Prebys Medical Discovery Institute are associated with the cells that fight viruses in the body, known as interferons.
The lead author of the study, Prof. Sumit K. Chanda, stated that the team’s objective was to gain new insights into the body’s response to the SARS-CoV-2 infection and find out what drove a weak or strong response to infection. Chanda, who is also the institute’s Immunity and Pathogenesis Program director, explained that through its study, the researchers were able to improve their understanding of how the virus manipulated the cells it invaded in the human body.
Soon after the pandemic began, researchers discovered that a weak interferon response to the infection caused the most serious coronavirus cases. This information led Chanda and his partners to begin looking for the human genes that were set off by interferons.
The researchers were able to develop lab experiments that could identify interferon-stimulated-genes that controlled the replication of the coronavirus’ cells, based on the information obtained from the SARS-CoV-1 virus, which bears some similarities to the SARS-CoV-2 infection. The former virus caused a relatively brief but fatal disease outbreak between 2002–2004.
Chanda revealed that researchers discovered that the SARS-CoV-2 infection was controlled by 65 interferon-stimulated-genes, which included some that impeded the ability of the virus to penetrate cells; he added that they also found that some of these genes displayed control across unrelated viruses, including the West Nile, seasonal flu and HIV.
The study’s first author, Laura Martin-Sancho, stated that the information they discovered was important and that they would be focusing on unearthing more information about the virus’ biology by studying whether genetic variability in these interferon-stimulated-genes correlated with the severity of a coronavirus infection. Martin-Sancho also noted that they would be looking into the biology of the SARS-CoV-2 variants, which threaten the effectiveness of vaccines by mutating, adding that they’d already begun collecting the variants for lab experiments.
Chanda concluded that it was important to continue with research efforts on the disease, despite the presence of vaccines that are helping to contain the pandemic.
Research efforts aren’t only being directed at the coronavirus infection. Other companies, such as Brain Scientific Inc. (OTCQB: BRSF), are devoting their energies to other health challenges such as the need to improve neurological diagnostics.
NOTE TO INVESTORS: The latest news and updates relating to Brain Scientific Inc. (OTCQB: BRSF) are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Immunotherapy has emerged as a key weapon in the fight against cancer. However, nearly 80% of patients either don’t respond to…
Cardiovascular disease remains the leading cause of death in the United States. One of the most persistent…
The scale and consequences of cardiovascular disease reinforce why innovation in this space remains essential.…
New research has mapped how breast tissues change as women age. The findings help to explain why breast…
During a recent House hearing conducted by the Ways and Means Committee, hospital CEOs were put on the…
Most cancer patients report cognitive deterioration, such as memory loss and difficulty concentrating as they…